Showing results (891-900 of 1,008) with videos related to

Sort By:
Pageof 101
Epidemics|August 6, 2019
Estimating the impact of violent events on transmission in Ebola virus disease outbreak, Democratic Republic of the Congo, 2018-2019S Rae Wannier, Lee Worden, Nicole A Hoff, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|May 29, 2020
Invasive squamous cell carcinomas and precursor lesions on UV-exposed epithelia demonstrate concordant genomic complexity in driver genesLorena Lazo de la Vega, Nolan Bick, Kevin Hu, et al.
Clinical and Translational Radiation Oncology|January 13, 2022
Imaging response assessment for predicting outcomes after bioselection chemotherapy in larynx cancer: A secondary analysis of two prospective trialsLaila A Gharzai, Julia Pakela, Elizabeth M Jaworski, et al.
The New England Journal of Medicine|October 11, 2016
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and NeckRobert L Ferris, George Blumenschein, Jerome Fayette, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 14, 2008
EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancerBhavna Kumar, Kitrina G Cordell, Julia S Lee, et al.
Science Advances|November 17, 2023
Attribution of individual methane and carbon dioxide emission sources using EMIT observations from spaceAndrew K Thorpe, Robert O Green, David R Thompson, et al.
European Archives of Oto-Rhino-Laryngology : Official Journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : Affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery|March 21, 2020
Predictors of survival in patients undergoing oropharyngeal surgery for cancer recurrence after radiation therapyMolly E Heft Neal, Julia Brennan, Catherine T Haring, et al.
Cancer Medicine|December 8, 2022
Biomarkers predictive of response to pembrolizumab in head and neck cancerDavid G Pfister, Robert I Haddad, Francis P Worden, et al.
The Lancet. Oncology|June 28, 2017
Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trialKevin J Harrington, Robert L Ferris, George Blumenschein, et al.
The Oncologist|April 6, 2021
Patient Burden with Current Surveillance Paradigm and Factors Associated with Interest in Altered Surveillance for Early Stage HPV-Related Oropharyngeal CancerLaila A Gharzai, Nicholas Burger, Pin Li, et al.
Pageof 101